Clinical Trial Update: A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation study of carfilzomib with thalidomide and dexamethasone in relapsed AL amyloidosis has completed Phase 1/2, with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis

Drugs mentioned

• Carfilzomib (carfilzomib)
• Thalidomide (thalidomide)
• dexamethone (dexamethasone)

Snippet

Sponsor: University College, London | Conditions: Amyloidosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-04-15